相关实验视频

Updated: Sep 12, 2025

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

一种基于CFTR的ARPKD新型基因疗法

Cristian Ciobanu^1,2, Patricia Outeda³, William B Guggino²

¹Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States.

American journal of physiology. Gastrointestinal and liver physiology

|August 5, 2025

概括

使用基因相关病毒 (AAV1) 针对异常胆道的基因疗法对治疗自体逆性多囊性病 (ARPKD) 有望. 这种方法减少了小鼠模型中的囊大小和面积,提供了潜在的治疗策略.

科学领域:

遗传学和分子生物学
肝病学和胃肠道学
儿科脏病学儿科脏病学

背景情况:

自体递归多囊性病 (ARPKD) 是一种严重的遗传疾病,其特征是胆道异常,导致肝脏和脏中的囊形成.
目前ARPKD的治疗方法有限,专注于治疗症状和并发症,突出显示了对新治疗策略的需求.
在ARPKD中,囊衍生胆细胞的顶端表面表现出高水平的特定酸部分 (MAL),这表明它是基因治疗载体的潜在目标.

研究的目的:

研究针对ARPKD异常胆道的基因疗法的可行性和治疗潜力.
在ARPKD小鼠模型中,评估携带截断的囊性纤维化跨膜导电性调节器 (CFTR) 基因的腺相关病毒 (AAV1) 载体在减少肝囊负担方面的疗效.
在ARPKD病理的背景下,确定AAV基因治疗的最佳目标.

主要方法:

腺相关病毒血清型1 (AAV1) 载体的内注射,编码GFP或截断的CFTR (Δ27-264-CFTR) 给1个月大的Pkhd1小鼠,这是ARPKD的模型.
在治疗后两个月评估肝囊的面积和大小.
通过分子方法检测载体基因组和mRNA表达,并通过免疫光技术定位蛋白质,包括用Maackia amurensis (MAL) 和Sambucus nigra (SNA) 莱克染色的酸染色.

主要成果:

与GFP载体或未经治疗的对照对待的小鼠相比,用CFTR载体治疗的小鼠表现出明显减少的肝囊面积和大小.
载体基因组和相应的mRNA表达仅在接受各自载体的小鼠中检测到,证实了成功的基因传递.
免疫光检测证实了GFP和CFTR蛋白在胆管细胞中的存在,CFTR显示治疗后从顶端到底侧膜的局部位置发生变化,MAL光素染色突出了囊表面作为目标.

结论:

使用基于AAV1的载体提供截断的CFTR的基因疗法是ARPKD的可行和潜在的治疗策略.
针对异常的胆管,特别是囊层胆管细胞的酸丰富的尖端表面,是ARPKD中AAV基因疗法传递的有效方法.
这项研究为开发基因治疗方法提供了一个有希望的临床前基础,以缓解与ARPKD相关的肝病理.

关键词:

一个 AAV1 一个 AAV1 在 ARPKD 里.在CFTR中,CFTR是最重要的.囊 (cysts) 是一种囊.酸是酸的一种.

更多相关视频

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...